Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Tenax Therapeutics, Inc.

Specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension

NASDAQ:TENX

Tenax Therapeutics, Inc.

Last Close

3.64

18/04 20:00

Market Cap

3.01M

Beta: 2.17

Volume Today

21.27K

Avg: 3.72M

PE Ratio

−20.44

PFCF: −0.36

locale

market

industry

website

crunchbase

linkedin

founding date

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics

Please Sign In To Use The Chat